Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bagatell, R.
Right arrow Articles by Whitesell, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bagatell, R.
Right arrow Articles by Whitesell, L.
Clinical Cancer Research Vol. 7, 2076-2084, July 2001
© 2001 American Association for Cancer Research

Regular Articles

Destabilization of Steroid Receptors by Heat Shock Protein 90-binding Drugs

A Ligand-independent Approach to Hormonal Therapy of Breast Cancer1

Rochelle Bagatell2, Omar Khan, Gillian Paine-Murrieta, Charles W. Taylor, Shiro Akinaga and Luke Whitesell

Department of Pediatrics, Steele Memorial Children’s Research Center [R. B., O. K., L. W.], and Arizona Cancer Center [G. P-M., C. W. T.], University of Arizona, Tucson, Arizona 85724, and Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., Shizuoka 100, Japan [S. A.]

Steroid hormone receptors have become an important target in the management of breast cancers. Despite a good initial response rate, however, most tumors become refractory to current hormonal therapies within a year of starting treatment. To address this problem, we evaluated the effects of agents that bind the molecular chaperone heat shock protein 90 (Hsp90) on estrogen receptor function in breast cancer. Unstimulated estrogen and progesterone receptors exist as multimolecular complexes consisting of the hormone-binding protein itself and several essential molecular chaperones including Hsp90. We found that interaction of the Hsp90-binding drugs geldanamycin and radicicol with the chaperone destabilizes these hormone receptors in a ligand-independent manner, leading to profound and prolonged depletion of their levels in breast cancer cells cultured in vitro. Consistent with these findings, in vivo administration of the geldanamycin derivative 17-allylaminogeldanamycin (17AAG; NSC330507) to estrogen-supplemented, tumor-bearing SCID mice resulted in marked depletion of progesterone receptor levels in both uterus and tumor. Drug administration also delayed the growth of established, hormone-responsive MCF-7 and T47D human tumor xenografts for up to 3 weeks after the initiation of therapy. We conclude that in light of their novel mechanism of anti-hormone action, consideration should be given to examining the activity of 17AAG and other Hsp90-binding agents in patients with refractory breast cancer in future clinical trials, either alone or in combination with conventional hormone antagonists.




This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
N. B. Berry, M. Fan, and K. P. Nephew
Estrogen Receptor-{alpha} Hinge-Region Lysines 302 and 303 Regulate Receptor Degradation by the Proteasome
Mol. Endocrinol., July 1, 2008; 22(7): 1535 - 1551.
[Abstract] [Full Text] [PDF]

Home page
 Plant CellHome page
N. P. Thao, L. Chen, A. Nakashima, S.-i. Hara, K. Umemura, A. Takahashi, K. Shirasu, T. Kawasaki, and K. Shimamoto
RAR1 and HSP90 Form a Complex with Rac/Rop GTPase and Function in Innate-Immune Responses in Rice
PLANT CELL, December 1, 2007; 19(12): 4035 - 4045.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Fiskus, Y. Ren, A. Mohapatra, P. Bali, A. Mandawat, R. Rao, B. Herger, Y. Yang, P. Atadja, J. Wu, et al.
Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-{alpha} Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90
Clin. Cancer Res., August 15, 2007; 13(16): 4882 - 4890.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. M. Trauernicht, S. J. Kim, N. H. Kim, and T. G. Boyer
Modulation of Estrogen Receptor {alpha} Protein Level and Survival Function by DBC-1
Mol. Endocrinol., July 1, 2007; 21(7): 1526 - 1536.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. S. Nowakowski, A. K. McCollum, M. M. Ames, S. J. Mandrekar, J. M. Reid, A. A. Adjei, D. O. Toft, S. L. Safgren, and C. Erlichman
A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer.
Clin. Cancer Res., October 15, 2006; 12(20): 6087 - 6093.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. Ray, X. Hou, H.-E. Zhou, H. Wang, and S. K. Das
Bip Is a Molecular Link between the Phase I and Phase II Estrogenic Responses in Uterus
Mol. Endocrinol., August 1, 2006; 20(8): 1825 - 1837.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
E. Oxelmark, J. M. Roth, P. C. Brooks, S. E. Braunstein, R. J. Schneider, and M. J. Garabedian
The Cochaperone p23 Differentially Regulates Estrogen Receptor Target Genes and Promotes Tumor Cell Adhesion and Invasion.
Mol. Cell. Biol., July 1, 2006; 26(14): 5205 - 5213.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
L. Lipfert, J. E. Fisher, N. Wei, A. Scafonas, Q. Su, J. Yudkovitz, F. Chen, S. Warrier, E. T. Birzin, S. Kim, et al.
Antagonist-Induced, Activation Function-2-Independent Estrogen Receptor {alpha} Phosphorylation
Mol. Endocrinol., March 1, 2006; 20(3): 516 - 533.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Fan, A. Park, and K. P. Nephew
CHIP (Carboxyl Terminus of Hsc70-Interacting Protein) Promotes Basal and Geldanamycin-Induced Degradation of Estrogen Receptor-{alpha}
Mol. Endocrinol., December 1, 2005; 19(12): 2901 - 2914.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
K-M Rau, H-Y Kang, T-L Cha, S A Miller, and M-C Hung
The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers
Endocr. Relat. Cancer, September 1, 2005; 12(3): 511 - 532.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Chen, S. Meng, H. Wang, P. Bali, W. Bai, B. Li, P. Atadja, K. N. Bhalla, and J. Wu
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824
Mol. Cancer Ther., September 1, 2005; 4(9): 1311 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T.-L. Cha, L. Qiu, C.-T. Chen, Y. Wen, and M.-C. Hung
Emodin Down-Regulates Androgen Receptor and Inhibits Prostate Cancer Cell Growth
Cancer Res., March 15, 2005; 65(6): 2287 - 2295.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. P. Goetz, D. Toft, J. Reid, M. Ames, B. Stensgard, S. Safgren, A. A. Adjei, J. Sloan, P. Atherton, V. Vasile, et al.
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
J. Clin. Oncol., February 20, 2005; 23(6): 1078 - 1087.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
S. Matsuzaki, M. Canis, C. Vaurs-Barriere, J.L. Pouly, O. Boespflug-Tanguy, F. Penault-Llorca, P. Dechelotte, B. Dastugue, K. Okamura, and G. Mage
DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissection
Mol. Hum. Reprod., October 1, 2004; 10(10): 719 - 728.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
T. M. Griffin, T. V. Valdez, and R. Mestril
Radicicol activates heat shock protein expression and cardioprotection in neonatal rat cardiomyocytes
Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1081 - H1088.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
J. Kim, S. Felts, L. Llauger, H. He, H. Huezo, N. Rosen, and G. Chiosis
Development of a Fluorescence Polarization Assay for the Molecular Chaperone Hsp90
J Biomol Screen, August 1, 2004; 9(5): 375 - 381.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Kaur, D. Belotti, A. M. Burger, K. Fisher-Nielson, P. Borsotti, E. Riccardi, J. Thillainathan, M. Hollingshead, E. A. Sausville, and R. Giavazzi
Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin: An Orally Bioavailable Heat Shock Protein 90 Modulator
Clin. Cancer Res., July 15, 2004; 10(14): 4813 - 4821.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Zhang, W. Wu, Y. Du, S. J. Santos, S. E. Conrad, J. T. Watson, N. Grammatikakis, and K. A. Gallo
Hsp90/p50cdc37 Is Required for Mixed-lineage Kinase (MLK) 3 Signaling
J. Biol. Chem., May 7, 2004; 279(19): 19457 - 19463.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. O. Nielsen, H. N. Andrews, M. Cheang, J. E. Kucab, F. D. Hsu, J. Ragaz, C. B. Gilks, N. Makretsov, C. D. Bajdik, C. Brookes, et al.
Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival: Potential for Intervention with 17-Allylamino Geldanamycin
Cancer Res., January 1, 2004; 64(1): 286 - 291.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Beliakoff, R. Bagatell, G. Paine-Murrieta, C. W. Taylor, A. E. Lykkesfeldt, and L. Whitesell
Hormone-Refractory Breast Cancer Remains Sensitive to the Antitumor Activity of Heat Shock Protein 90 Inhibitors
Clin. Cancer Res., October 15, 2003; 9(13): 4961 - 4971.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
K. De Bosscher, W. Vanden Berghe, and G. Haegeman
The Interplay between the Glucocorticoid Receptor and Nuclear Factor-{kappa}B or Activator Protein-1: Molecular Mechanisms for Gene Repression
Endocr. Rev., August 1, 2003; 24(4): 488 - 522.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. P. Goetz, D. O. Toft, M. M. Ames, and C. Erlichman
The Hsp90 chaperone complex as a novel target for cancer therapy
Ann. Onc., August 1, 2003; 14(8): 1169 - 1176.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Banumathy, V. Singh, S. R. Pavithra, and U. Tatu
Heat Shock Protein 90 Function Is Essential for Plasmodium falciparum Growth in Human Erythrocytes
J. Biol. Chem., May 9, 2003; 278(20): 18336 - 18345.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. Chiosis, H. Huezo, N. Rosen, E. Mimnaugh, L. Whitesell, and L. Neckers
17AAG: Low Target Binding Affinity and Potent Cell Activity--Finding an Explanation
Mol. Cancer Ther., February 1, 2003; 2(2): 123 - 129.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Neckers
Heat Shock Protein 90 Inhibition by 17-Allylamino-17- demethoxygeldanamycin: A Novel Therapeutic Approach for Treating Hormone-refractory Prostate Cancer : Commentary re: D. B. Solit et al., 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and Her-2/neu and Inhibits the Growth of Prostate Cancer Xenografts. Clin. Cancer Res., 8: 986-993, 2002.
Clin. Cancer Res., May 1, 2002; 8(5): 962 - 966.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2001 by the American Association for Cancer Research.